Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003–2005)

Hammond, Tara N.; Pesillo‐Crosby, S. Anna

doi:10.2460/javma.232.4.553

Cited by 116 publications

(132 citation statements)

References 13 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…About 50 per cent of splenic submissions to pathology laboratories demonstrate benign changes (eg, haematoma [Fig 6] and nodular hyperplasia) and the remaining 50 per cent are malignancies. About 25 per cent of dogs presenting with non-traumatic haemoabdomen have a benign haematoma rather than a malignancy (Hammond and Pesillo-Crosby 2008, Aronsohn and others 2009). Haemangiosarcomas account for up to 80 per cent of malignancies, with the remainder comprising lymphomas, mast cell tumours, leiomyosarcomas, fibrosarcomas, osteosarcomas and malignant fibrous histiocytomas (Spangler and Kass 1997).…”

Section: Specific Splenic Conditionsmentioning

confidence: 99%

Investigation and management of splenic disease in dogs

Hayes¹,

Ladlow²

2012

In Practice

View full text Add to dashboard Cite

Splenic disorders are a significant cause of morbidity and mortality in middle‐aged and older dogs, and a spectrum of presentations is possible, from chronic non‐specific clinical signs to a rapidly fatal haemoabdomen. Splenomegaly is commonly recognised during clinical examination or imaging in practice, but it can be difficult to decide whether the primary problem is within the spleen itself (eg, a focal mass, in which case a splenectomy is generally the treatment of choice) or whether the splenomegaly represents systemic disease (eg, a lymphoma or immune‐mediated haemolytic anaemia, in which case a biopsy may be useful but a splenectomy may be contraindicated). Splenic surgery requires an appreciation of the vascular anatomy, and adequate monitoring as well as supportive treatment may be critical to the outcome of surgery. This article discusses the anatomy of the spleen and how to investigate splenomegaly, as well as how to perform a (partial) splenectomy and the possible complications involved.

show abstract

Section: Specific Splenic Conditionsmentioning

confidence: 99%

Investigation and management of splenic disease in dogs

Hayes¹,

Ladlow²

2012

In Practice

View full text Add to dashboard Cite

show abstract

“…Several studies have reported approximately 70% of dogs with non-traumatic hemoperitoneum had hemangiosarcoma [1–3]. Hemoperitoneum is reported in 63–80% of dogs with hemangiosarcoma, compared with only 30% of dogs with benign splenic masses [4, 5].…”

Section: Introductionmentioning

confidence: 99%

A comparison of microRNA expression profiles from splenic hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs

et al. 2016

View full text Add to dashboard Cite

BackgroundSplenic masses are common in older dogs; yet diagnosis preceding splenectomy and histopathology remains elusive. MicroRNAs (miRNAs) are short, non-coding RNAs that play a role in post-transcriptional regulation, and differential expression of miRNAs between normal and tumor tissue has been used to diagnose neoplastic diseases. The objective of this study was to determine differential expression of miRNAs by use of RNA-sequencing in canine spleens that were histologically confirmed as hemangiosarcoma, nodular hyperplasia, or normal.ResultsTwenty-two miRNAs were found to be differentially expressed in hemangiosarcoma samples (4 between hemangiosarcoma and both nodular hyperplasia and normal spleen and 18 between hemangiosarcoma and normal spleen only). In particular, mir-26a, mir-126, mir-139, mir-140, mir-150, mir-203, mir-424, mir-503, mir-505, mir-542, mir-30e, mir-33b, mir-365, mir-758, mir-22, and mir-452 are of interest in the pathogenesis of hemangiosarcoma.ConclusionsFindings of this study confirm the hypothesis that miRNA expression profiles are different between canine splenic hemangiosarcoma, nodular hyperplasia, and normal spleens. A large portion of the differentially expressed miRNAs have roles in angiogenesis, with an additional group of miRNAs being dysregulated in vascular disease processes. Two other miRNAs have been implicated in cancer pathways such as PTEN and cell cycle checkpoints. The finding of multiple miRNAs with roles in angiogenesis and vascular disease is important, as hemangiosarcoma is a tumor of endothelial cells, which are driven by angiogenic stimuli. This study shows that miRNA dysregulation is a potential player in the pathogenesis of canine splenic hemangiosarcoma.

show abstract

“…[20][21][22][23][24][25][26] There have been no studies specifically evaluating the treatment of dogs with grossly metastatic HSA, a common presentation in the cases of HSA. 8,10,12 Nonresectable, primary, noncutaneous HSA appears to carry a negative prognosis for overall survival (OS), yet the use of chemotherapy or palliative radiation therapy has been largely unexplored. 27 This study evaluated the efficacy of a combination chemotherapy protocol comprised of doxorubicin, dacarbazine, and vincristine (DAV) for the treatment of advanced-stage canine noncutaneous HSA.…”

Section: Introductionmentioning

confidence: 99%

“…7,8 Many patients present with internal bleeding due to tumor rupture or disseminated intravascular coagulation. 2,[9][10][11][12] Surgery may be palliative to arrest active hemorrhage, but does not provide long-term survival for the majority of cases with visceral involvement. 8,11,13,14 Chemotherapy in the adjuvant setting has been evaluated in various clinical studies and has shown promise in prolonging life after surgical resection of the primary HSA lesion.…”

Section: Introductionmentioning

confidence: 99%

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Dervisis

Domı́nguez

Newman

et al. 2011

Journal of the American Animal Hospital Association

View full text Add to dashboard Cite

Hemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days.Significant toxicities were noted, including 41 high-grade hematologic and 12 high-grade gastrointestinal toxic events.

show abstract

Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003–2005)

Cited by 116 publications

References 13 publications

Investigation and management of splenic disease in dogs

Investigation and management of splenic disease in dogs

A comparison of microRNA expression profiles from splenic hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs

Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Contact Info

Product

Resources

About